"MetaVia OXM analogue agonist meets endpoints in Phase Ib weight loss trial" was originally created and published by Clinical ...

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a lower risk for acute asthma exacerbations in ...

G protein-coupled receptors (GPCRs) are essential for cell signal transduction and comprise the largest drug target protein family. Upon agonist stimulation, these receptors activate multiple ...

Peptides have emerged as critical tools in the investigation of physiological homeostasis, specifically in how biological systems manage energy substrates and recover from physical trauma. By ...

Please provide your email address to receive an email when new articles are posted on . SAN FRANCISCO — In patients with metabolic-associated steatotic liver disease or metabolic-associated ...

In early 2025, around 4.9 million British adults - almost one in ten - are estimated to have recently used, or expressed ...

Breakthrough Therapy Designation is intended to expedite the development and review of medicines that are intended to treat a serious or life-threatening condition and have shown preliminary clinical ...

MetaVia has shared an update on its attempt to crash the obesity party, reporting average weight loss of 9.1% in people who ...

Genetic inactivation of the kidney glucagon receptor (GCGR) in mice causes abnormalities in renal health and metabolic dysregulation, with symptoms resembling those of chronic kidney disease (CKD) in ...

Biomed Industries to Advance NA-931 Into Two Global Phase 3 Trials as Monotherapy and in Combination With Semaglutide and Tirzepatide for Obesity Advancing NA-931 into two Phase 3 programs as ...